IQVIA Set to Report Q4 Earnings: Here's What You Should Know

Core Insights - IQVIA Holdings Inc. (IQV) is scheduled to release its fourth-quarter 2025 results on February 5, with a history of surpassing earnings estimates, averaging a surprise of 1.6% over the last four quarters [1] Revenue Expectations - The Zacks Consensus Estimate for IQV's revenues is $4.2 billion, reflecting a year-over-year growth of 7.2% [2] - The Technology & Analytics (TAS) segment is expected to generate revenues of $1.8 billion, indicating a 6.9% increase from the previous year, driven by drug launches and a strong commercial portfolio [2] - For the Research & Development segment, revenues are estimated at $2.3 billion, suggesting a 7.7% year-over-year increase, supported by a 20% growth in Request for Proposals in Q3 2025 [3] - The Contract Sales & Medical segment's revenues are projected at $193.2 million, representing a 9.1% increase from the prior year, attributed to large multi-year engagements [4] Geographic Revenue Breakdown - Revenue from the Americas is estimated at $2 billion, indicating an 8.1% increase year-over-year [5] - For Europe and Asia, the revenue estimate stands at $1.3 billion, suggesting a 3.8% rise from the previous year [5] - Asia-Pacific revenues are projected to reach $882.6 million, reflecting a 9.4% year-over-year growth [5] Earnings Per Share - The consensus estimate for earnings per share is $3.4, indicating a 9% growth compared to the previous year [5] Earnings Prediction Model - The current model does not predict a definitive earnings beat for IQVIA, with an Earnings ESP of 0.00% and a Zacks Rank of 2 (Buy) [6]